Quantum-Si Business Summary

Quantum-Si Inc (QSI) operates a high-margin razor-and-blade business model, generating revenue through the sale of its semiconductor-based protein sequencing instruments (Platinum® Pro and the upcoming Proteus™ platform), proprietary consumable kits (v3 Library Prep and sequencing reagents), and specialized software services. The company’s primary business segments are centered on Next-Generation Protein Sequencing (NGPS) and single-molecule detection, targeting a $75 billion total addressable market across drug discovery, clinical proteomics, and basic research. Management has designated 2026 as a strategic "transition year," projecting approximately $1 million in revenue as it prioritizes consumable utilization and market preparation for the late-2026 launch of Proteus, a high-throughput platform priced at $425,000. Quantum-Si competes directly with Nautilus Biotechnology, Olink (Thermo Fisher Scientific), Encodia, and Pacific Biosciences, positioning itself as a disruptive, benchtop-accessible alternative to traditional mass spectrometry and high-cost proteomic workflows. The company was founded in 2013 by Dr. Jonathan Rothberg, a serial biotech innovator and National Medal of Technology recipient known for pioneering high-speed DNA sequencing at 454 Life Sciences and Ion Torrent. The current leadership team is led by President and CEO Jeff Hawkins, who brings over 20 years of experience from Illumina and Truvian Sciences, and CFO Jeffry Keyes, who oversees the firm’s $215.8 million cash reserve. Technical development is spearheaded by CTO Todd Rearick, an engineering veteran of Ion Torrent and Hyperfine, alongside Chief Product Officer John Vieceli, PhD, and Chief Commercial Officer Todd Bennett. Quantum-Si is backed by prominent institutional investors including ARK Investment Management, Foresite Capital, and Kleiner Perkins. Its board of directors features industry heavyweights such as Paula Dowdy (formerly of Illumina), Jack Kenny (Meridian Bioscience), and Scott Mendel (Akoya Biosciences), reflecting a deep pedigree in life sciences commercialization and semiconductor-integrated biology.